Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

A Multicentre, Open, Uncontrolled Study to Assess Quality of Life During Six Cycles (24 Weeks) of Treatment With an Oral Contraceptive Containing 30 µg of Ethinylestradiol and 3 mg of Drospirenone (Yasmin).

The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Inclusion Criteria:

• Female requiring contraceptives.
• Aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker.
• Regular menstrual cycle (defined as duration of 28 +/- 5 days).

Exclusion Criteria:

• No Contraindication for OC use